GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT03160261

CompletedPhase 4

Effect of Exenatide on Cortisol Secretion

Lead sponsor

University of Tartu

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criterion

—

Primary endpoint

•Cortisol peak

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03160261

Org study IDEx17

Timeline

Milestones

Study first posted2017-05-19actual

Study start2017-09-07actual

Primary completion2017-12-28actual

Study completion2017-12-28actual

Last update posted2018-05-03actual

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Age 18-50 years

•Body weight >65 kg

Exclusion criteria

•Presence of chronic illness

•daily use of any medicines

•pregnancy, lactation

•use of oral contraceptives during previous 2 months

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Cardiometabolic biomarkers

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Glucose

Time frame:Glucose measured every 30 minutes during 2 hours after injection

Postprandial glucose

descriptive, improvement

Cardiometabolic biomarkers

2 endpoints

Other/protocol endpoint

heart rate

Time frame:every 30 minutes during 2 hours after injection

Heart rate, change

change from baseline, improvement

Other/protocol endpoint

Blood pressure

Time frame:every 30 minutes during 2 hours after injection

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Other/protocol endpoint

nausea

Time frame:every 30 minutes during 2 hours after injection

Nausea

descriptive

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

Cortisol peak

Time frame:every 30 minutes during 2 hours after injection

concentration, descriptive

Secondary/protocol endpoint/low confidence

Adrenocorticotropin (ACTH) peak

Time frame:every 30 minutes during 2 hours after injection

concentration, descriptive

Secondary/protocol endpoint/low confidence

Growth hormone

Time frame:every 30 minutes during 2 hours after injection

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers.
Diabetes therapy : research, treatment and education of diabetes and related disorders2023 Apr (month)PMID36800161doi:10.1007/s13300-023-01381-wvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.